

Statistical Research and Applications Branch, NCI, Technical

Report # 2007-02

Modeling Population-Based Cancer Survival Trends Using Joinpoint Survival Models

Binbing Yu, Lan Huang, Ram C. Tiwari,
Karen A. Johnson, and Eric J. Feuer

November 28, 2007

Abstract

In the United States cancer as a whole is the second leading cause of death and a major burden to health care, thus the medical progress against cancer is a major public health goal. There are many individual studies to suggest that cancer treatment breakthroughs and early diagnosis have significantly improved the prognosis of cancer patients. To better understand the relationship between medical improvements and the survival experience for the patient population at large, it is useful to evaluate cancer survival trends on the population level, e.g., to find out when and how much the cancer survival rates changed. In

this paper, we analyze the population-based grouped cancer survival data by incorporating joinpoints into the survival models. A joinpoint survival model facilitates the identification of trends with significant change points in cancer survival, when related to cancer treatments or interventions. The Bayesian Information Criterion is used to select the number of joinpoints. The performance of the joinpoint survival models is evaluated with respect to cancer prognosis, joinpoint locations, annual percent changes in death rates by year of diagnosis, and sample sizes through intensive simulation studies. The model is then applied to the grouped relative survival data for several major cancer sites from the Surveillance, Epidemiology and End Results (SEER) Program of the National Cancer Institute. The change points in the survival trends for several major cancer sites are identified and the potential driving forces behind such change points are discussed.

KEY WORDS: Annual percentage change, BIC, relative survival, joinpoint model, proportional hazards, SEER.

1 INTRODUCTION

In recent decades, there has been considerable progress against cancer due to improvement in treatment, the development of cancer prevention, and the dissemination of early diagnosis and cancer screening techniques. These medical advances improved both the quality of life and the length of survival, permitting many survivors to continue full and productive lives. Joinpoint

models (Kim et al. 2000) have been used to characterize cancer trends and progress as connected linear segments. The Cancer Statistics Review (Ries et al. 2006), an annual publication of the NCI, reports the trends of cancer incidence and mortality rates, using the joinpoint models. First issued in 1998, the Annual Report to the Nation, a collaboration among the NCI, the Centers for Disease Control and Prevention (CDC), the American Cancer Society (ACS), and the North American Association of Central Cancer Registries (NAACCR), also provides updated information on cancer incidence and mortality rates in the United States obtained from the joinpoint models. These trends help in understanding the impact of cancer control and interventions on cancer incidence and mortality. However, there is no analogous method for reporting trends in cancer survival, which is also an important measure for monitoring and evaluating the impact of early diagnosis and treatment breakthroughs.

Medical breakthroughs impact survival of patients diagnosed in a specific time frame. Including the joinpoints into the survival models enables us to identify and evaluate the impact of important medical breakthroughs. Feuer et al. (1991) and Weller et al. (1999) have modeled the impact of treatment breakthroughs on survival in testicular cancer and Hodgkins disease using joinpoint regression. In their work two joinpoints occur when a medical development is changing survival as a function of the year of diagnosis; the first joinpoint when the intervention is introduced, and the second one is when survival levels off, indicating the end of dissemination through the population. However, they only assumed a fixed number of joinpoints and do

not solve the more general problem of determining the number of joinpoints.

The Surveillance, Epidemiology, and End Results (SEER) Program of the NCI is an authoritative source of information on cancer incidence and survival in the U.S. SEER currently collects and publishes cancer incidence and survival data from population-based cancer registries, now covering approximately 26 percent of the US population. In this article, we extend the use of the joinpoint model to the grouped survival data from the SEER Program. Hence, the results are representative of the general population in the U.S. The main goal of the Joinpoint survival model (JPSM) is to describe the trends in cancer survival, i.e., to find out when the cancer survival starts to improve; and, if there is a leveling off of such realized improvement, how much of an improvement was finally attained.

The rest of the paper is organized as follows. In Section 2, we propose the JPSM for population-based grouped cancer survival data, and describe the estimation method and the model selection criteria. While mainly developed for population-based grouped survival data, the method could also be applied to any arbitrary interval-censored survival data. Extensive simulation studies are carried out to assess the performance of the JPSMs in Section 3. In Section 4, the JPSMs are applied to the grouped cancer survival data for several major cancer sites from the SEER Program. Finally, the advantages and the utilities of the JPSMs are discussed.

2 JOINTPOINT SURVIVAL MODEL

Let x be the calendar time, which reflects the possible change point of cancer survival trends. In cancer survival studies, the survival time is usually defined as the time from diagnosis to death. We assume that the hazard rate of dying at time t follows a proportional hazards model with

$$\lambda(t|x) = \lambda_0(t) \exp\{h(x)\}, \quad (1)$$

where $\lambda_0(t)$ is the baseline hazard and

$$h(x) = \beta x + \sum_{k=1}^K \delta_k (x - \tau_k)^+ + \gamma' z, \quad (2)$$

indicates the trend of survival with respect to calendar time x . Here, $u^+ = u$ if $u > 0$ and $= 0$ otherwise. Throughout the paper, we use x to denote the year of diagnosis. The other covariates z , e.g., race, sex, and comorbidity status, can also be included in $h(x)$. For simplicity, we omit the covariate z from now onwards. In the model, the regression parameters are $\beta, \delta_1, \dots, \delta_K$. The τ_1, \dots, τ_K are called the joinpoints because the function $h(x)$ is continuous at, but has different slopes before and after, τ_1, \dots, τ_K . The continuity constraint on $h(x)$ at the joinpoints is more realistic as the effect of the new treatment or intervention on the hazard rate usually takes place gradually. We call the survival model, with $h(x)$ defined as in (2), a K -joinpoint JPSM. There are a total of $(K + 1)$ segments, and for the k -th segment, the slope coefficient is $\beta_k = \beta + \sum_{l=1}^{k-1} \delta_l, k = 1, \dots, K + 1$.

The baseline hazard $\lambda_0(t)$ can be modeled, for example, by a time-dependent function such as regression spline (Rosenberg 1995). Some authors have con-

sidered modeling $\lambda_0(t)$ using one discontinuous change point, see, for example, Liang et al. (1990), Luo et al. (1997) and Lim et al. (2002), among others. Recently, Goodman et al. (2006) considered a multiple change point model and a multiple joinpoint model for the baseline hazard. So far, there is no literature on the multiple joinpoint models for the survival trends. Therefore, rather than focus on change points in the baseline hazard, we are interested in modeling the trend in cancer survival by introducing joinpoints following the calendar time of cancer diagnosis. For the population-based cancer survival data, e.g., the SEER survival data, the survival times after diagnosis are usually grouped into intervals $I_j = [t_{j-1}, t_j), j = 0, \dots, J$, where $t_0 = 0$, and t_J is the end of the follow-up. We call it grouped survival data. The death rate during the interval I_j given that a patient is alive at the beginning of the interval is

$$\lambda_j(x) = P(T < t_j | T \geq t_{j-1}; x) = 1 - \frac{S(t_j|x)}{S(t_{j-1}|x)}, \quad j = 1, \dots, J. \quad (3)$$

Under the proportional hazards assumption, the survival function is given by

$$S(t|x) = S_0(t)^{\exp\{h(x)\}}, \quad (4)$$

where $S_0(t)$ is the baseline survival function, and

$$\log \left\{ -\log [1 - \lambda_j(x)] \right\} = \log \left\{ -\log \left[\frac{S_0(t_j)}{S_0(t_{j-1})} \right] \right\} + h(x). \quad (5)$$

Let $\alpha_j = \log \left\{ -\log \left[\frac{S_0(t_j)}{S_0(t_{j-1})} \right] \right\}$. Then, the baseline survival function can be expressed as $S_0(t_j) = \exp[-\sum_{l=0}^j e^{\alpha_l}]$.

When there is no joinpoint, $h(x) = \beta x$ and we have $\exp(\beta) = \frac{\log(1-\lambda_j(x+1))}{\log(1-\lambda_j(x))}$. If the death rates $\lambda_j(x)$ are small for $j = 1, \dots, J$, then $\exp(\beta) - 1 \approx$

$\frac{\lambda_j(x+1)-\lambda_j(x)}{\lambda_j(x)}$. Thus, $[\exp(\beta)-1]100\%$ can be interpreted as the annual percent change (APC) of the death rates, $\lambda_j(x)$, with respect to the diagnosis year x . A negative value of the APC means that the death rates $\lambda_j(x)$ decrease as x increases. When $h(x)$ is defined by a joinpoint model (2), the APC of the death rates in the k -th segment is $APC_k = [\exp(\beta_k) - 1]100\%$. In sequel, we use $\boldsymbol{\theta} = (\boldsymbol{\alpha}, \beta, \boldsymbol{\delta}, \boldsymbol{\tau})^T$, where $\boldsymbol{\alpha} = (\alpha_1, \dots, \alpha_J)$, $\boldsymbol{\delta} = (\delta_1, \dots, \delta_K)$, $\boldsymbol{\tau} = (\tau_1, \dots, \tau_K)$.

2.1 The Likelihood function for the grouped cancer survival data

When we evaluate the progress and trend in cancer survival, it is ideal that the confounding effects of death from other causes are removed. The cancer net survival is a hypothetical quantity that measures the excess mortality due to the cancer of interest as if other causes of death are eliminated. There are two common measures of net survival, namely, the cause-specific survival and the relative survival. In cause-specific survival analysis, the cause of death is identified and used. The event is the death due to the cancer of interest and the people dying from other causes or lost to follow-up are considered as censored. For the patient cohort diagnosed in the year x , let n_{xj} be the number of people alive at the beginning of interval I_j , let d_{xj} be the number of cancer deaths and let l_{xj} be the number of patients lost to follow-up or dying from other causes in interval I_j . By the actuarial assumption (Gail, 1975), the adjusted number of person-years at risk is $r_{xj} = n_{xj} - \frac{1}{2}l_{xj}$ and the number of cancer deaths in I_j follows a binomial distribution, i.e.,

$d_{xj} \sim \text{Bin}(r_{xj}, \lambda_j(x))$. Hence, the likelihood function for the cause-specific grouped survival data $\mathcal{D} = \{x, (r_{xj}, d_{xj}), j = 1, \dots, J\}$ is

$$L(\boldsymbol{\theta}|\mathcal{D}) = \prod_x \prod_{j=1}^J \{\lambda_j(x)\}^{d_{xj}} \{1 - \lambda_j(x)\}^{r_{xj} - d_{xj}}. \quad (6)$$

The cause-specific survival analysis requires accurate information on cause of death. The accuracy of death certificates for determining the underlying cause of death is problematic in some situations (Percy 1981). An alternative method of estimating cancer net survival is to use the relative survival ratio (Ederer et al. 1961), defined as the observed survival proportion in the patient group divided by the expected survival rate of a comparable group from the general population, who are assumed to be practically free of the cancer of interest. Both measures estimate the same conceptual quantity, i.e., cancer specific net survival, although in different ways. The major advantage of the relative survival is that the information on cause of death is not required, thereby circumventing problems with the inaccuracy or non-availability of death certificates. In relative survival analysis, the cause of death is not used. Let d_{xj} denote the number patients dying from all causes and l_{xj} denote the number of patients lost to follow-up during interval I_j . The conditional probability of surviving the interval I_j from all causes is $p_j(x)E_j(x)$, where $p_j(x) = 1 - \lambda_j(x)$ is the interval relative survival probability and $E_j(x)$ is the expected probability of surviving interval I_j for the general population. We assume that d_{xj} follows a binomial distribution $d_{xj} \sim \text{Bin}(r_{xj}, 1 - p_j(x)E_j(x))$. The likelihood function for the relative

survival data $\mathcal{D} = \{x, (r_{xj}, d_{xj}, E_{xj}), j = 1, \dots, J\}$ is

$$L(\boldsymbol{\theta}|\mathcal{D}) = \prod_x \prod_{j=1}^J \left\{ 1 - p_j(x)E_j(x) \right\}^{d_{xj}} \left\{ p_j(x)E_j(x) \right\}^{r_{xj} - d_{xj}}. \quad (7)$$

Here, $E_j(x)$ are calculated from the life tables for the matched general population (National Center for Health Statistics, 2003).

2.2 Parameter estimation

When the covariates are fixed, the likelihood functions (6) and (7) correspond to generalized linear models with complementary log-log link function. For this case, the estimation methods have been described by Prentice and Gloeckler (1978), and Hakulinen and Tenkanen (1987). If the locations of the joinpoints, τ_1, \dots, τ_K , are known, then $(x - \tau_1)^+, \dots, (x - \tau_K)^+$ are fixed and the above available methods apply. When the locations of the joinpoints are not known, we can use the grid search method (Lerman 1980) to find the estimates of joinpoints. We assume that the joinpoints only occur at the observed data points, i.e., $\tau_k \in \Xi, k = 1, \dots, K$, where Ξ is the set of observed x values. Let $\ell(\boldsymbol{\theta}) = \log L(\boldsymbol{\theta}|\mathcal{D})$ be the loglikelihood function. First the loglikelihood is maximized for fixed values of $\boldsymbol{\tau} = (\tau_1, \dots, \tau_K)$ and the associated estimates of $(\boldsymbol{\alpha}, \beta, \boldsymbol{\delta})$ are denoted by $(\hat{\boldsymbol{\alpha}}_{\boldsymbol{\tau}}, \hat{\beta}_{\boldsymbol{\tau}}, \hat{\boldsymbol{\delta}}_{\boldsymbol{\tau}})$. The maximum loglikelihood value of $\ell(\boldsymbol{\theta})$ for given $\boldsymbol{\tau}$ is a profile loglikelihood. All possible combinations of the joinpoints are tried by grid search and the maximum likelihood estimates (MLEs) of the joinpoints, $\hat{\boldsymbol{\tau}}$ are the values that maximize $\ell_{\boldsymbol{\tau}}$. Thus, the MLE of the parameters is $\hat{\boldsymbol{\theta}} = (\hat{\boldsymbol{\alpha}}_{\hat{\boldsymbol{\tau}}}, \hat{\beta}_{\hat{\boldsymbol{\tau}}}, \hat{\boldsymbol{\delta}}_{\hat{\boldsymbol{\tau}}}, \hat{\boldsymbol{\tau}})$.

The asymptotic distribution theory in the joinpoint regression has been

proved by Feder (1975a,b). With this approach, ℓ_{\max} is the maximum value of $\ell_{\boldsymbol{\tau}}$ and $\ell_{\boldsymbol{\tau}}(\tau_1, \dots, \tau_K | \tau_k = x)$ is the maximum value of $\ell_{\boldsymbol{\tau}}$ conditional on $\tau_k = x$. Then the $100(1 - q)\%$ confidence interval (CI) for τ_k includes the x values such that

$$-2\left\{\ell_{\boldsymbol{\tau}}(\tau_1, \dots, \tau_K | \tau_k = x) - \ell_{\max}\right\} \leq (\chi_1^2)^{-1}(q), \quad (8)$$

where $(\chi_1^2)^{-1}(q)$ is the quantile function of a chi-squared distribution with one degree of freedom.

Feder (1975b, p.53) proved that when the number of data points n goes to infinity, the MLE $\hat{\boldsymbol{\theta}}$ has the same asymptotic normal distribution as the estimates for the data with a small number of observations deleted near the true joinpoints. In practice, the standard errors of the MLEs $(\hat{\boldsymbol{\alpha}}, \hat{\boldsymbol{\beta}}, \hat{\boldsymbol{\delta}})$ are estimated by fitting the JPSM after deleting the data points that are on the estimated joinpoints $\hat{\tau}_1, \dots, \hat{\tau}_K$ (Lerman 1980; Feder 1975b). The standard errors for the slopes $\hat{\beta}_k, k = 1, \dots, K + 1$, and that of the estimated survival function $S(t|x, \hat{\boldsymbol{\theta}})$ can be calculated from the delta method using Equations (4) and (2). The CIs for β_k are obtained from the normal approximation and the CIs for APC_k can be transformed from the CIs for $\beta_k, k = 1, \dots, K + 1$. Kim et al. (2006) have showed by simulations that the CIs for $\hat{\boldsymbol{\beta}}$ from this approach have good coverage rates. In practice, we limit the maximum number of joinpoints to 3 because the patient's survival usually improves gradually and changes in survival are few in number. Also, we impose the restriction that two joinpoints may not be too close to each other and that a joinpoint may not occur too early or too late in the study period. We

also restrict that, after excluding the joinpoints, the minimum number of data points between two consecutive joinpoints is 2 and that the minimum number of data points from a joinpoint to either end of the data is 2.

2.3 Model selection

There are several methods available for model selection, such as the Akaike's information criterion (AIC) (Akaike 1973) and the Bayesian Information Criterion (BIC) (Schwarz 1978). The AIC tends to over fit the true model and the BIC is consistent when the number of true covariates does not increase with the sample size (Yang 2006; Zheng and Loh 1995). The BIC has been used for selecting the number of joinpoints in Bayesian models (Tiwari et al. 2005). Kim et al. (2000) used permutation tests for model selection in the joinpoint models for rates and proportion. The permutation-test based (PTB) model selection approach consists of a series of permutation tests for $H_0 : K = k_0$ against $H_1 : K = k_1$. This model selection method for cancer incidence and mortality rates has been developed by the NCI (<http://srab.cancer.gov/joinpoint>). The PTB approach can also be used to pick the joinpoint number. The test for $H_0 : K = k_0$ against $H_1 : K = k_1$ is carried out by permuting the residuals.

The PTB approach can also be used to select the number of joinpoints in JPSM. Let $\hat{\lambda}_j(x)$ be the predicted value of $\lambda_j(x)$ in (3) under the null model. The predicted value for the number of deaths d_{xj} is given by $\hat{d}_{xj} = r_{xj}\hat{\lambda}_j(x)$ and its variance $V_{xj} = r_{xj}\hat{\lambda}_j(x)\{1 - \lambda_j(x)\}$. Then the residuals $\hat{d}_{xj} - d_{xj}$ are

standardized to e_{xj} with mean 0 and variance 1. The permuted residuals, e_{xj}^* are added back to create permuted samples d_{xj}^* , where

$$d_{xj}^* = \hat{d}_{xj} + r_{xj}^* \sqrt{V_{xj}}.$$

Let $F(\mathcal{D})$ be the F -type statistic for testing the difference between the null and alternative model using the original data \mathcal{D} . Because the joinpoints are estimated, $F(\mathcal{D})$ no longer follows an asymptotic F distribution, and its empirical distribution has to be estimated from the permuted sample \mathcal{D}^* . The p -value is the proportion of times that $F(\mathcal{D}^*) > F(\mathcal{D})$ over a large number of permutations.

However, it is computationally too intensive to use the PTB approach for the survival data in practice. There are two major contributions of the difference in computation time using the PTB approach for model selection on survival data and for age-adjusted mortality and incidence rates (Kim et al. 1999). First, fitting linear trend for grouped survival data involves maximizing the loglikelihood (6) or (7), which is an iterative calculation and thus is much slower than the simple linear regression for rates. Second, there is only one observation of rates per year, but L observations of follow-up intervals for survival for each diagnosis year, where L is the difference between the diagnosis year and the end of follow-up. For example, for the people diagnosed from 1975 to 2002 with study cutoff date December 31, 2002, the maximum follow-up time is 27 years for the people diagnosed in 1975, and there is one less year follow-up for each diagnosis year ahead. In total there are $27+26+\dots+1=378$ observations. In contrast, there are only 28

observations of incidence or mortality rates for 1975 to 2002. To fit a single JPSM with fixed joinpoints it takes from 1000 to 5000 times longer with survival data than with a series of incidence or mortality data, depending on the number of joinpoints and the number of iterations necessary. To permute 378 observations takes about 75 times longer than permuting 28 observations. Since the fit of the JPSM's are nested within the permutations, the computing time for fitting a PTB survival model is therefore from $(1000 \times 75) = 75,000$ to $(5000 \times 75) = 375,000$ times longer than for an analogous incidence or mortality model. For a typical problem, it takes 5 seconds for incidence or mortality data considering to select from 0-3 joinpoints using a PTB approach with 4499 permutations using a Pentium (R) 4 3.00GHz CPU and 1.00G RAM, and it would take about 22 days to fit the analogous survival model. Hence, the permutation test is not practical for fitting JPSMs.

Alternatively, BIC is often used as a model selection criterion in frequentist settings (Burham and Anderson, 2004). Based on an empirical study, Kim et al. (2006) compared the BIC with the PTB approach and found that, although liberal, the BIC approach is much less computationally intensive and is a strong competitor of the PTB approach. The AIC is even more liberal, and tends to pick a higher number of joinpoints. Therefore, we use the BIC for model selection. Let M_K denote a K -joinpoint model and let ℓ_K be the maximum loglikelihood value of model M_K as defined in (6) or (7), then

$$BIC(M_K) = -2\ell_K + p_K \log n, \quad (9)$$

where n is the total number of follow-up years for all diagnosis years and p_K is the number of parameters under model M_K . For JPSM M_K with a maximum J years of follow-up, $p_K = J + 1 + 2K$. If the possible range of the number of joinpoints is from 0 to, a pre-defined value, K_{\max} , the BIC approach selects the model M_K with the minimum BIC as the final model.

3 SIMULATION STUDY

The purpose of the simulation study is to evaluate how well the proposed JPSM picks the correct number of joinpoints during a long study period. The grouped survival data are simulated with various combinations of the number of new cancer incidences diagnosed each year, severity of the cancer, number of joinpoints, locations of the joinpoints and the APC of the death rates. The simulation study may provide a general reference of the performance of the method before they analyze the population-based survival data in practice. To avoid the use of the expected survival, we assume that the cause of death is known and use cause-specific analysis in the simulation. The results can be generalized to the relative survival case.

We consider the range of the diagnosis year as $x = 0, 1, \dots, 27$, representing 1975 to 2002 in the SEER data. The study cutoff year is the end of the 27th year, so the maximum follow-up time is 27 years. After examining the new cancer cases diagnosed in each year in period 1975-2002 from the real SEER data, we found that the average numbers of new cases each year are over 5000 for the most common cancer sites, are around 1000-2000 for the common

cancer sites and are in hundreds for the rare cancer sites. To simulate the grouped survival data, we assume that in each calendar year, there are 5000, 1000 and 500 new cancer cases diagnosed, representing the most common, common, and rare cancer sites in the SEER 9 registries. These numbers correspond to n_{x1} , the number of people alive in the beginning of the first interval I_1 for each calendar year x . The number of people dying from other causes in the interval j is generated as a binomial variable $l_{xj} \sim \text{Bin}(n_{xj}, p_{0j})$, where p_{0j} are the probabilities of dying from other causes from the US life tables (Anderson, 1999) for the people with age $(65+j)$, which is approximate the average age of cancer diagnosis. Hence the adjusted number of people at the risk of cancer death is $r_{xj} = n_{xj} - \frac{1}{2}l_{xj}$. The numbers of cancer deaths $d_{xj}, j = 1, \dots, 27$, are generated using the binomial distributions for cause-specific survival data described in Section 2.1, where the death rate $\lambda_j(x)$ is calculated from (3). The number of people alive at the beginning of the interval $j + 1$ is $n_{x,j+1} = n_{xj} - l_{xj} - d_{xj}$.

Cure becomes a possibility for many cancers if diagnosed early. The mixture cure models (Boag 1949; Farewell 1982; Gamel et al. 2000; Yu et al. 2004), which postulate that a fraction of the patients are cured from the disease of interest, are widely used to model the survival data from clinical studies as well as population-based cancer survival studies. In the simulation study, we use the mixture cure model and the exponential model without cure as the baseline survival function $S_0(t)$. The baseline survival function $S_0(t) = c + (1 - c) \exp(-t/\mu)$, where c is the cure fraction and μ is the mean survival time in years for uncured patients. When $c = 0$, it reduces to an

exponential model. For the purpose of illustration, the parameters (c, μ) are set to be $(0, 60)$, $(0, 20)$ and $(0, 4)$ for the exponential model and $(0.7, 10)$, $(0.4, 5)$ and $(0.1, 2)$ for the mixture cure model to represent cancer with best, moderate, and poor survival rates, respectively. The corresponding survival curves are shown in Figure 1. Notice that the population of patients with $(c = 0, \mu = 60)$ or $(c = 0.7, \mu = 10)$ have the best chance of survival and can live for a longer time, thus leaving not much room for the improvement in survival. For the patients with $(c = 0, \mu = 4)$ or $(c = 0.1, \mu = 2)$, the survival is poor, so if there is a big treatment improvement of the disease, it is easier to observe an increase in survival and to detect a significant joinpoint in the trend.

The performance of the JPSM is also associated with the number and the locations of joinpoints. The total number of joinpoints K is selected to be 0, or 1, or 2. There are a total of 13 different choices of the joinpoints and the APC values as specified in Table 1. For example, there is no joinpoint in Case 1, one joinpoint at varying locations in Cases 2-7, and two joinpoints for Cases 8-13. In order to see whether the JPSM can detect the change occurring close to the end of study, some joinpoints are set to the year 23. For Case 2, there is one joinpoint at $\tau_1 = 10$ with APC=-5% before, and APC=0% after, the year 10. The difference of the APC in the two segments 0-10 and 10-27 is 5%. When the difference of the APCs in two consecutive segments is big, we expect to detect that joinpoint, but when the difference is small, there is less chance to detect the joinpoint.

The percentages of picking the correct number of joinpoints in different

scenarios are shown in Table 2. The effects of different parameter specifications are summarized below:

- Effect of sample size: For common cancer with the number of new cases $n = 5000$ every year, the JPSM finds the correct number of joinpoints most of the time. As the number of new cases decreases to $n = 1000$, the estimated number of joinpoints \hat{K} tends to be less than the true K . For $n = 500$, the model tends to find no joinpoint.
- Effect of cancer prognosis: The JPSMs select a lower number of joinpoints for less severe cancer with high survival rates. For the same value of APC, the higher baseline death rate $\lambda_j(x)$ implies a larger absolute difference in death rates $\lambda_j(x+1) - \lambda_j(x)$. For example, if APC=-20%, then the referent death rate $\lambda_j(x) = 50\%$ induces an absolute reduction of 10% in death rates, while the $\lambda_j(x) = 10\%$ only leads to a 2% decrease in death rates. Thus, JPSMs have more capability to detect a joinpoint when the baseline death rates are high.
- Effect of the number of joinpoints: The chance of capturing the correct total number of joinpoints is higher for smaller K . When the true model is M_0 , the percentages of selecting the correct model are close to 100% for all the data with different size and severity status, which implies that the false alarm rate of a significant improvement in survival is very low if there is no trend variation. For the Cases 2-7 where the number of joinpoints $K \geq 1$, there is a tendency to underestimate the total number of joinpoints, i.e., the JPSMs tend to be conservative.

- Effect of the locations of joinpoints: As the people diagnosed more recently have less follow-up, the JPSMs are not able to detect a joinpoint when the true joinpoint is very close to the end of the study period. See, e.g., Cases 6 and 7 with joinpoint located at 23, which is only 4 years away from the last year in the study. Even though, there exist some improvements in trend, there is not enough follow-up time to allow the model to detect the difference. Therefore, the closer are the joinpoints to the beginning or to the end of the study period, the harder it is to detect the joinpoints. These issues are worse near the end of the study period since the follow-up time is shorter.
- Effect of the change in APC on death rates: The model selection method tends to select a lower number of correct models when the APCs for the two consecutive segments are -5% and -2% (with absolute difference 3%) compared with those with APC=-5% and 0% or APC=0% and -5% (with absolute difference 5%). So larger changes in APC lead to better performance of the model for detecting the joinpoint.
- Effect of cure fraction c : The difference is minor between the standard survival model and the mixture cure model when the survival level is the same. For example, the percentage of correctly selecting one joinpoint is 99.4% for data with $(c, \mu) = (0.7, 10)$ and 99.1% for data with $(c, \mu) = (0, 50)$ when $n = 5000$ for Case 2. From Figure 1, the outcomes of these two cases are very close.

Generally, the JPSMs are conservative with low false alarm rate or Type I error, especially when the patient’s survival prognosis is good (less severe) and the cancer is rare.

4 APPLICATION

The SEER registries routinely collect data on patient demographics, primary tumor site, morphology, stage at diagnosis, first course of treatment, follow-up for vital status, etc. The SEER Program began collecting data on cancer cases in 1973, in the states of Connecticut, Iowa, New Mexico, Utah, and Hawaii and the metropolitan areas of Detroit and San Francisco-Oakland. In 1974-1975, the metropolitan area of Atlanta and the 13-county Seattle-Puget Sound area were added. These original 9 regions are referred to as the SEER 9 registries, covering 10% of the US population. Because of their long history, we apply the JPSM to the survival data from the SEER 9 registries from 1975 to 2002, which is the most recent year with complete follow-up information. To avoid the inaccuracy of the cause of death information, we use the relative survival data.

We start by presenting the survival trends for all cancer sites combined for males and for females (Figure 2a, b). The estimates of the joinpoints and APC are shown in Table 3. The standard errors of the APCs are not reported. Instead, the significant differences of the APC values are marked with asterisks. For men, the trend in survival is divided into four segments demarcated by joinpoints in 1988 (95% CI, 1987-1990), 1992 (95% CI, 1991-

1993) and 1995 (95% CI, 1994-1996). The slopes of the four segments reveal that the APC in mortality was decreasing significantly by 2.1% in the first segment, by 8.5% in the second segment, and was not significantly different from zero with APC=0.7% and -2.5% for the last two segments. The joinpoints for 1988 and 1992 are suggestive of changes that were taking place in prostate cancer screening and diagnosis. The large and significant changes in prostate cancer incidence in 1989 and 1992 appear to be responsible for the major details of the overall survival curve for males. Because the prostate cancer contribution to the overall survival curve is related to several factors including PSA screening, a more detailed analysis and discussion is needed to address the organ specific details that contribute to the blended composite. With prostate cancer incidence included in the overall model, it is difficult to interpret what portion of the trend is artificial, or in other words generated by well recognized sources of bias. The introduction of screening in a population causes survival to improve, since the time of diagnosis is shifted to an earlier time point, even if the time of death is unchanged (lead time bias). In addition, screening can detect some cancers that never would have produced symptoms, if screening had not detected the cancer (over-diagnosis bias). Consequently, we elected to obtain a survival progress measure independent of prostate cancer, by generating a survival model for all male cancer excluding prostate. In this model, a single joinpoint remained for 1993 (95% CI, 1990-1995), with a steady significant improvement in survival through 1993 (APC=-1.3%) and with an acceleration of the improvement after that (APC=-1.9%). While screening influences cancers sites other than prostate

cancer and colorectal cancer, factors that artificially increase survival are influenced mostly by the rapid introduction of screening, where prostate cancer is by far the prime example.

We used a similar approach to examine the survival of females from cancer at all sites. The trend in overall survival for women was marked by joinpoints in 1982 (95% CI, 1979-1983) and 1986 (95% CI, 1984-1990), with the largest APC amounting to -2.9% in the middle segment, and a slowing of the improvements after that (APC=-1.4%) (Table 3). Major advances in adjuvant endocrine and multi-agent chemotherapy for breast cancer treatment influenced survival over this period. However, screening mammography undoubtedly affected trends in breast cancer incidence during the 1980s, introducing some level of artifact into the survival trends. When breast cancer cases were removed, the model showed significant improvements from 1981 (95% CI, 1979-1983) through 1994 (95% CI, 1992-1998) with APC=-0.6% and an acceleration after that (APC=-1.5%). The approach that we have used shows that it is preferable to examine joinpoints in organ specific survival curves when looking for their connection to patterns of care.

To illustrate the utility of the JPSM and certain characteristics of our results, we have selected three additional organ site examples: distant testicular cancer, distant pancreatic cancer, and regional melanoma (Figure 3). For distant testicular cancer in Figure 3a, two joinpoints observed in 1977 (95% CI, 1976-1979) and 1993 (95% CI, 1988-1997) separate 3 phases of survival improvement for distant testicular cancer. Distant testicular cancer is highlighted because the circumstances surrounding changes in survival of tes-

ticular cancer patients are particularly well documented. In the earliest time period, the APC of death rates is decreasing 32.2% each year. This period of dramatic survival improvement stabilizes in 1977 followed by a period of moderate but consistent gains in late stage survival from 1977 to 1993. Then in the period following 1993, the survival for late stage disease ceases to improve. In Figure 3b the data for distant pancreatic cancer also reveal a single joinpoint, indicating a modest change in survival in this subgroup starting in 1995 (95% CI, 1993-1998) and corresponding to a 2.9% annual improvement. For regional melanoma in Figure 3c, a single joinpoint is observed in 1998 (95% CI, 1996-1999). This joinpoint heralds a large improvement in survival corresponding to an APC of 14.8%.

Our confidence in the JPSM approach is strengthened by the data for testicular cancer. Changes in survival for testicular cancer are closely linked with the introduction of platinum therapy in 1974, a development which enabled a dramatic improvement in the survival of distant stage testicular cancer patients prior to 1977. The gain in survival in these patients was largely related to an increased cure fraction (Huang et al. 2007). From 1977 to 1993, the more modest gains in survival correspond to the optimization of platinum-based, multi-agent therapy. The decline in survival for distant stage testicular cancer after 1993 is probably associated with an increase of biologically aggressive disease in the distant stage category, as observed in other study populations. (Sonneveld et al. 1999) Over time, the stage distribution of testicular cancer has changed so that more Stage 1 cancer is diagnosed in conjunction with less of all other stages combined. This

evidence of earlier detection is consistent with a shift to earlier stages of more indolent tumors with their extended opportunity for detection, leaving the more virulent and rapidly progressing forms of the disease to be diagnosed in the late stage setting.

Moving away from diagnoses where evolving patterns of care and their impact are relatively well characterized, it could not have been anticipated that JPSM would uncover a statistically significant joinpoint in the survival profile for regional melanoma or for distant pancreatic cancer. For regional melanoma, our results suggest that a change in practice somewhat prior to 1998 started a trend for a sizable increase in the survival of patients with a diagnosis of regional melanoma. This result underscores the difficulty in understanding a trend that is premised on data from a limited number of cases (259) subject to uncontrolled factors. From a review of clinical trials for patients receiving systemic adjuvant therapy for melanoma, there is no clear cut evidence that a breakthrough has been achieved or that long-term survival has been extended (Verma et al. 2006). However, after a landmark trial of high-dose Interferon alfa-2b (IFN alpha-2b) in 1996, (Kirkwood et al. 1996) a case can be made that increasing use of IFN alpha-2b may have contributed to improved survival. Indeed, a meta-analysis of 12 randomized trials suggested that recurrence free survival was improved by IFN alpha-2b with a statistically significant benefit associated with increasing dose (Wheatley et al. 2003). Based on this kind of information, it might be useful to return to the records for the regional melanoma cases involved in this study, to look for a trend of increasing interferon use in this cohort. In addition,

alternative hypotheses for an apparent improvement in survival could also be considered.

A change in surgical practice associated with regional melanoma might also be a factor that could influence survival. Lymphatic mapping with sentinel node biopsy was the basis for the Multi-center Selective Lymphadenectomy Trial (MSLT-1) that started in 1994 and completed accrual in 2002 (Morton et al. 2006). The participants in this trial were individuals with relatively advanced lesions (Clark level IV, V, or level III with intermediate thickness). With randomization to observation versus sentinel node biopsy with immediate clearing of the lymphatic basin for a positive sentinel node, the MSLT-1 showed that immediate lymphadenectomy increases the survival of patients with nodal metastases. The five year survival for immediate lymphadenectomy was 72% vs. 52% for delayed lymphadenectomy. However, it is debatable whether 1998 is a milestone in the use of sentinel node biopsy for melanoma patients. Nevertheless, the possibilities for explaining a survival trend of this magnitude starting in 1998 are limited in number. This experience highlights the potential for JPSM to improve cancer surveillance. When unrecognized trends are identified, there is an opportunity to return to the registries to collect additional data that may explain the trend and support wider application of beneficial interventions.

In the case of distant pancreatic cancer, JPSM has identified a trend in survival improvement starting in 1995. This result highlights another surveillance issue. Using SEER data from 1988 to 1999, investigators were able to appreciate survival improvements in distant pancreatic cancer when com-

paring 2-year survival rates for the years after 1992 compared with the years before 1991 (Riall et al. 2006). However, the authors noted that even though the trend they observed was statistically significant, they doubted that it was clinically significant. Using the more precise data obtained with JPSM, attention can be focused on identifying a change in treatment that could account for an improvement in survival starting around 1995. After many years when single agent 5-fluorouracil (5-FU) was the standard systemic treatment for unresectable pancreatic cancer, gemcitabine was approved for this indication by the FDA in May, 1996 (Storniolo et al. 1999). The introduction of this drug into practice is a likely explanation for a modest improvement in survival for patients with advanced pancreatic cancer. In a randomized clinical trial comparison of gemcitabine with 5-FU, patients treated with gemcitabine experienced a median survival extension of 5 weeks (Burris et al. 1997). The details of this example show that a relative improvement in survival for a cohort that experiences short survival can be pinpointed and identified as statistically significant; however, further information is needed to provide a scale to the benefit. Otherwise, large numbers of patients may serve as the basis for identifying statistically significant events of small magnitude without much insight as to benefit. In this event, the value of a more complex decision making model (Tennvall and Wilking, 1999) can be invoked, attempting an assignment of cost-effectiveness with the attendant risks of that process.

5 CONCLUSION

The JPSM is useful to describe the progress of cancer survival and to gain understanding about the effect of changes in medical practice. Although we used relative survival data in our application, it is also possible to use cause-specific survival data when the information on cause of death is more reliable. The JPSM can serve as a tool to find a potential change point in cancer survival. Compared to the cancer incidence or mortality trends, survival trends usually improve gradually, and there tends to be a smaller number of joinpoints. When evaluating survival, one must be aware of various biases introduced by screening and new diagnostic technologies, e.g., lead time, length bias and over diagnosis. For instance, screening mainly influences survival by detecting earlier, either earlier stage or event at a smaller size within stage, and this shift to earlier disease is hard to control. Hanin et al. (2006) presented a biologically motivated model of breast cancer development and detection, and examined the effect of screening schedules and clinical covariates at the time of diagnosis on survival. It is useful to incorporate the models for screening effect in the change point modeling.

So JPSM can be used when we have confidence in the effect of medical breakthroughs on survival or we are interested in the identification of possible change in trends. However, we need to be cautious about the possible biases due to screening or selection. It is not advised that one use the JPSM directly to evaluate the benefits of treatment using the population-based cancer survival data since the data are not from a randomized trial where

the treated and untreated group are balanced in confounders. That is also why we should look at improvements on a population level instead of using treatment information directly.

The simulation studies presented here evaluate the performance of the JPSM in picking the correct number of joinpoints. The model selection criterion used for the JPSM is the BIC, which tends to detect a lower number of joinpoints, especially when the sample size is small. An alternative model selection criterion such as AIC, which is more sensitive to changes in the trend could also be used. The focus of this paper is on the description of current survival trends and the identification of change points. However, the JPSM can also be used for the survival prediction. The standard survival models, such as the proportional hazards models, have been used to predict the survival rates for the newly diagnosed cancer patients (Mariotto et al. 2006). It is useful to compare the accuracy of the predictions resulting from the standard survival models with those from the JPSM.

As treatments progress, more and more patients are cured and become long-term survivors for certain types of cancers. The major medical breakthroughs can significantly increase the probability of cure as well as prolong the survival time for the uncured patients favoring the use of the mixture cure model. It is possible to include joinpoints in the mixture cure model to evaluate the change in trend for both cure fraction and the survival times for the uncured patients. Even though the JPSM described is primarily for cancer survival data, it can be applied to other similar survival data. Adding change points to the baseline hazard for relative survival data is useful to ex-

amine the survivals of cancer patients and general population, for example, whether the patients and general population have the same survival rates.

References

- Anderson, R.N. (1999), "Method for constructing complete annual U.S. life tables," *Vital Health Statistics Report, Series 2* **129**, 136.
- Akaike, H. (1973), "Information theory as an extension of the maximum likelihood principle," P. 267-281 in B. N. Petrov and F. Csaksi, editors. *2nd International Symposium on Information Theory*. Akademiai Kiado, Budapest, Hungary.
- Burham, K.P. and Anderson, D.R. (2004), "Multimodel inference: understanding AIC and BIC in model selection," *Sociological Methods and Research*, **33**, 261-304.
- Burris, H.A., Moore, M.J., Andersen, J., Green, M.R., Rothenberg, M.L., Modiano, M.R., Cripps, M.C., Portenoy, R.K., Storniolo, A.M., Tarassoff, P., Nelson, R., Dorr, F.A., Stephens, C.D., Von Hoff, D.D. (1997), "Improvements in survival and clinical benefit with gemcitabine as first-line therapy for patients with advanced pancreas cancer: a randomized trial," *Journal of Clinical Oncology*, **15**, 2403-2413.
- Ederer, F., Axtell, L.M., Cutler, S.J. (1961), *The relative survival rate: A statistical methodology*. National Cancer Institute Monograph; **6**, 101-

121.

Edwards, B.K., Brown, M.L., Wingo, P.A., Howe, H.L., Ward, E., Ries, L.A.G., Schrag, D., Jamison, P.M., Jemal, A., Wu, X.C., Friedman, C., Harlan, L., Warren, J., Anderson, R.N. and Pickle, L.W. (2005), “Annual report to the nation on the status of cancer, 1975-2002, featuring population-based trends in cancer treatment,” *Journal of National Cancer Institute*, **97**, 1407-1427.

Feder, P.I. (1975)a, “On asymptotic distribution theory in segmented regression problems-identified case,” *Annals of Statistics*, **3**, 49-83.

Feder, P.I. (1975)b, “The log likelihood ratio in segmented regression,” *Annals of Statistics*, **3**, 84-97.

Feuer, E.J., Kessler, L.G., Baker, S.G., Triolo, H.E., and Green, D.T. (1991), “The impact of breakthrough clinical trials on survival in population based tumor registries,” *Journal of Clinical Epidemiology*, **44**, 141-153.

Gail, M. (1975), “A review and critique of some models used in competing risk analysis,” *Biometrics*, **31**, 209-222.

Hakulinen, T., and Tenkanen, L. (1987), “Regression analysis of relative survival rates,” *Applied Statistics*, **36**, 309-317.

Hanin, L.G., Miller, A., Zorin, A.V., and Yakovlev, A.Y. (2006), “The University of Rochester Model of Breast Cancer Detection and Survival,”

Journal of the National Cancer Institute, Monographs **36**, 66-78.

Kim, H.J., Fay, M.P., Feuer, E.J. and Midthune, D.N. (2000), "Permutation tests for joinpoint regression with applications to cancer rates," *Statistics in Medicine*, **19**, 335-351.

Kirkwood, J.M., Strawderman, M.H., Ernstoff, M.S., Smith, T.J., Borden, E.C. and Blum, R.H. (1996), "Interferon alfa-2b adjuvant therapy of high-risk resected cutaneous melanoma: the Eastern Cooperative Oncology Group Trial EST 1684," *Journal of Clinical Oncology*, **14**, 7-17.

Lerman, P.M. (1980), "Fitting segmented regression models by grid search," *Applied Statistics*, **29**, 77-84.

Liang, K.Y., Self, S.G., and Liu, X. (1990), "The Cox proportional hazards model with change point: an epidemiologic application," *Biometrics*, **46**, 783-793.

Lim, H., Sun, J., and Matthews, D.E. (2002), "Maximum likelihood estimation of a survival function with a change point for truncated and interval-censored Data," *Statistics in Medicine*, **22**, 743-752.

Luo, X., Turnbull, B.W., and Clark, L.C. (1997), "Likelihood ratio tests for a change point with survival data," *Biometrika*, **84**, 555-565.

Mariotto, A., Wesley, M.N., Cronin, K.A., Johnson, K.A., and Feuer, E.J. (2006), "Estimates of long-term survival for newly diagnosed cancer patients: a projection approach," *Cancer*, **103**, 2039-2050.

- McCullagh, P., and Nelder, J.A. (1989), *Generalized linear models*. Chapman & Hall/CRC.
- Morton, D.L., Thompson, J.F., Cochran, A.J., Mozzillo, N., Elashoff, R., Essner, R., Nieweg, O.E., Roses, D.F., Hoekstra, H.J., Karakousis, C.P., Reintgen, D.S., Coventry, B.J., Glass, E.C., Wang, H., for the MSLT Group. (2006), "Sentinel-node biopsy or nodal observation in melanoma," *The New England Journal of Medicine*, **355**, 1307-1317.
- National Center for Health Statistics (2003) National vital statistics reports. vol 52 no 9. Hyattsville, Maryland.
- Percy, C., Stanek, E. III., and Gloeckler, L. (1981), "Accuracy of cancer death certificates and its effect on cancer mortality statistics," *American Journal of Public Health*, **71**, 242250.
- Prentice, P.L. and Gloeckler, L.A. (1978), "Regression analysis of grouped survival data with applications to breast cancer data," *Biometrics*, **34**, 57 - 67.
- Riall, T.S., Nealon, W.H., Goodwin, J.S., Zhang, D., Kuo, Y.F., Townsend, C.M., and Freeman, J.L. (2006), "Pancreatic Cancer in the General Population: Improvements in Survival Over the Last Decade," *Journal of Gastrointestinal Surgery*, **10**, 1212-1224.
- Ries, L.A.G., Harkins, D., Krapcho, M., Mariotto, A., Miller, B.A., Feuer, E.J., Clegg, L., Eisner, M.P., Horner, M.J., Howlader, N., Hayat,

- M., Hankey, B.F. and Edwards, B.K. (2006), *SEER Cancer Statistics Review, 1975-2003*, National Cancer Institute. Bethesda, MD, http://seer.cancer.gov/csr/1975_2003/.
- Rosenberg, P.S. (1995), "Hazard function estimation using B-splines," *Biometrics*, **51**, 874-887.
- Samuels, M.L., and Howe, C.D. (1970), "Vinblastine in the management of testicular cancer," *Cancer*, **25**, 1009-1017.
- Schwarz, G. (1978), "Estimating the dimension of a model," *Annals of Statistics*, **6**, 461-464.
- Sonneveld, D.J.A., Hoekstra, H.J., Van der Graaf, W.T.A., Sluiter, W.J., Schraffordt Koops, H., and Sleijfer, D.T. (1999), "The changing distribution of stage in nonseminomatous testicular germ cell tumours, 1977 to 1996," *BJU International*, **84**, 68-74.
- Storniolo, A.M., Enas, N.H., Brown, C.A., Voi, M., Rothenberg, M.L., and Schilsky, R. (1999), "An investigational new drug treatment program for patients with gemcitabine," *Cancer*, **85**, 1261-1268.
- Surveillance Research Program, Cancer statistics Branch, DCCPS, National Cancer Institute. 2006. SEER*Stat Database: Mortality-Public-Use, Total U.S (1969-2001).
- Tennvall, G.R., and Wilking, N. (1999), "Treatment of Locally Advanced Pancreatic Carcinoma in Sweden: A Health Economic Comparison

of Palliative Treatment With Best Supportive Care Versus Palliative Treatment With Gemcitabine in Combination With Best Supportive Care,” *PharmacoEconomics*, **15**, 377-384.

Tiwari, R.C., Cronin, K.A., Davis, W., Feuer, E.J., Yu, B., and Chib, S. (2005), “Bayesian model selection for joint point regression with application to age-adjusted cancer rates,” *Applied Statistic*, **5**, 919-939.

Verma, S., Quirt, I., McCreedy, D., Bak, K., Charette, M., Iscoe, N., and Melanoma Disease Site Group of Cancer Care Ontario’s Program in Evidence-Based Care. (2006), “Systematic review of systemic adjuvant therapy for patients at high risk for recurrent melanoma”, *Cancer*, **106**, 1431-1442.

Weller, E.A., Feuer, E.J., Frey, C.M. and Wesley, M.N. (1999), “Parametric relative survival regression using generalized linear models with application to Hodgkin’s lymphoma,” *Applied Statistics*, **48**, 79-89.

Wheatley, K., Ives, N., Hancock, B., Gore, M., Eggermont, A., and Suci, S. (2003), “Does adjuvant interferon- α for high-risk melanoma provide a worthwhile benefit? A meta-analysis of the randomised trials,” *Cancer Treatment Reviews*, **29**, 241-252.

Yang, Y. (2005), “Can the strengths of AIC and BIC be shared? a conflict between model identification and regression estimation,” *Biometrika*, **92**, 937-950.

Yu, B., Tiwari, R.C., Cronin, K.A. and Feuer, E.J. (2004), "Cure fraction estimation from the mixture cure models for grouped survival data," *Statistics in Medicine*, **23**, 1733-1747.

Zheng, X. and Loh, W.Y. (1995). "Consistent variable selection in linear models," *Journal of the American Statistical Association*, **90**, 151-156.

Table 1: Locations of the joinpoints and APC values in the simulation for the K -joinpoint models

Case	K	(τ_1, \dots, τ_K)	$(APC_1, \dots, APC_{K+1})$
1	0		-2%
2	1	10	(-5%, 0%)
3	1	10	(-5%, -2%)
4	1	15	(-5%, 0%)
5	1	15	(-5%, -2%)
6	1	23	(-5%, 0%)
7	1	23	(-5%, -2%)
8	2	(10, 15)	(0%, -5%, 0%)
9	2	(10, 15)	(0%, -5%, -2%)
10	2	(10, 23)	(0%, -5%, 0%)
11	2	(10, 23)	(0%, -5%, -2%)
12	2	(15, 23)	(0%, -5%, 0%)
13	2	(15, 23)	(0%, -5%, -2%)




Figure 1: The baseline survival functions $S_0(t)$ used in the simulation

Table 2: Percentage of selecting different joinpoint models M_0 - M_3

(c, μ)	$n = 5000$				$n = 1000$				$n = 500$			
	M_0	M_1	M_2	M_3	M_0	M_1	M_2	M_3	M_0	M_1	M_2	M_3
Case 1: Model= M_0 , APC=-2%												
(0.7,10)	99.8	0.2	.	.	99.6	0.4	.	.	99.6	0.4	.	.
(0,60)	99.4	0.6	.	.	99.4	0.5	0.1	.	99.7	0.3	.	.
(0.4,5)	99.7	0.3	.	.	99.8	0.2	.	.	99.5	0.5	.	.
(0,20)	99.8	0.2	.	.	99.8	0.2	.	.	99.5	0.5	.	.
(0.1,2)	99.3	0.6	0.1	.	99.0	1.0	.	.	98.6	1.3	0.1	.
(0,4)	99.5	0.5	.	.	100.0	.	.	.	100.0	.	.	.
Case 2: Model= M_1 , JP=10, APC=(-5%, 0%)												
(0.7,10)	.	99.4	0.6	.	3.3	96.6	0.1	.	37.9	62.0	0.1	.
(0,60)	.	99.6	0.4	.	6.0	93.9	0.1	.	46.4	53.6	.	.
(0.4,5)	.	99.1	0.9	.	.	99.8	0.2	.	0.1	99.3	0.6	.
(0,20)	.	99.5	0.5	.	.	99.4	0.6	.	1.2	98.3	0.4	0.1
(0.1,2)	.	99.2	0.8	.	.	98.6	1.3	0.1	.	98.4	1.5	0.1
(0,4)	.	99.0	1.0	.	.	99.4	0.6	.	.	100.0	.	.
Case 3: Model= M_1 , JP=10, APC=(-5%, -2%)												
(0.7,10)	.	99.9	0.1	.	61.1	38.8	0.1	.	87.4	12.5	0.1	.
(0,60)	0.2	99.3	0.5	.	68.8	31.0	0.2	.	90.8	9.1	0.1	.
(0.4,5)	.	99.1	0.9	.	4.4	95.0	0.6	.	33.2	66.4	0.4	.
(0,20)	.	99.5	0.5	.	11.1	88.5	0.4	.	55.6	44.2	0.2	.
(0.1,2)	.	99.2	0.8	.	.	99.0	0.9	0.1	1.2	97.5	1.3	.
(0,4)	.	99.0	1.0	.	.	100.0	.	.	1.4	98.6	.	.
Case 4: Model= M_1 , JP=15, APC=(-5%, 0%)												
(0.7,10)	.	99.1	0.9	.	16.2	83.4	0.4	.	59.4	40.4	0.2	.
(0,60)	.	99.6	0.4	.	32.3	67.1	0.6	.	74.1	25.9	.	.
(0.4,5)	.	99.4	0.5	0.1	.	99.7	0.3	.	1.7	97.8	0.5	.
(0,20)	.	99.4	0.6	.	0.5	99.0	0.5	.	14.6	85.4	.	.
(0.1,2)	.	99.0	1.0	.	.	98.9	1.0	0.1	.	98.9	1.1	.
(0,4)	.	99.3	0.7	.	.	99.5	0.5	.	.	98.8	1.2	.
Case 5: Model= M_1 , JP=15, APC=(-5%, -2%)												
(0.7,10)	1.6	98.2	0.2	.	77.5	22.5	.	.	93.6	6.3	0.1	.
(0,60)	5.8	93.8	0.4	.	84.9	14.9	0.2	.	95.4	4.6	.	.
(0.4,5)	.	99.8	0.2	.	10.9	88.5	0.6	.	53.1	46.8	0.1	.
(0,20)	.	99.5	0.5	.	36.4	63.3	0.3	.	75.0	25.0	.	.
(0.1,2)	.	99.0	1.0	.	.	98.7	1.3	.	2.3	96.8	0.9	.
(0,4)	.	99.3	0.6	0.1	.	99.5	0.5	.	6.0	92.8	1.2	.
Case 6: Model= M_1 , JP=23, APC=(-5%, 0%)												
(0.7,10)	87.9	11.8	0.3	.	99.3	0.7	.	.	99.8	0.2	.	.
(0,60)	95.1	4.9	.	.	99.3	0.7	.	.	99.8	0.2	.	.
(0.4,5)	27.8	71.8	0.3	0.1	93.3	6.7	.	.	96.7	3.3	.	.
(0,20)	68.5	31.5	.	.	97.8	2.1	0.1	.	99.1	0.9	.	.
(0.1,2)	.	99.5	0.5	.	42.8	56.2	0.9	0.1	73.3	26.4	0.3	.
(0,4)	0.9	99.0	0.1	.	76.1	23.9	.	.	87.7	11.1	1.2	.
Case 7: Model= M_1 , JP=23, APC=(-5%, -2%)												
(0.7,10)	98.0	2.0	.	.	99.7	0.3	.	.	99.5	0.5	.	.
(0,60)	98.6	1.4	.	.	99.8	0.2	.	.	99.7	0.3	.	.
(0.4,5)	80.5	19.4	0.1	.	99.1	0.9	.	.	99.3	0.7	.	.
(0,20)	94.5	5.4	0.1	.	99.3	0.7	.	.	99.5	0.5	.	.
(0.1,2)	14.5	85.0	0.5	.	84.1	15.9	.	.	91.6	8.4	.	.
(0,4)	45.7	54.0	0.3	.	91.1	8.9	.	.	98.8	1.2	.	.

Table 2: Percentage of selecting different joinpoint models M_0 - M_3 (continued)


(c, μ)	$n = 5000$				$n = 1000$				$n = 500$			
	M_0	M_1	M_2	M_3	M_0	M_1	M_2	M_3	M_0	M_1	M_2	M_3
Case 8: Model= M_2 , JP=(10,15), APC=(0%, -5%, 0%)												
(0.7,10)	0.8	0.2	98.7	0.3	87.4	5.1	7.5	.	97.2	2.0	0.7	0.1
(0,60)	2.0	2.4	95.5	0.1	89.9	5.0	5.1	.	97.6	1.7	0.6	0.1
(0.4,5)	.	.	99.2	0.8	27.9	2.7	69.2	0.2	76.5	3.9	19.3	0.3
(0,20)	.	.	99.6	0.4	40.5	7.8	51.5	0.2	81.7	7.1	11.0	0.2
(0.1,2)	.	.	99.2	0.8	0.2	0.1	98.5	1.2	16.0	2.4	80.3	1.3
(0,4)	.	.	99.1	0.9	.	.	100.0	.	44.4	.	55.6	.
Case 9: Model= M_2 , JP=(10,15), APC=(0%, -5%, -2%)												
(0.7,10)	.	47.2	52.8	.	50.5	47.7	1.8	.	86.8	12.7	0.5	.
(0,60)	.	61.3	38.7	.	53.8	44.4	1.8	.	86.6	13.0	0.4	.
(0.4,5)	.	1.5	97.8	0.7	2.2	74.2	23.6	.	36.9	56.0	7.1	.
(0,20)	.	7.5	92.1	0.4	6.4	79.7	13.8	0.1	44.0	52.5	3.5	.
(0.1,2)	.	.	98.8	1.2	.	28.8	70.0	1.2	3.7	61.7	34.2	0.4
(0,4)	.	.	99.6	0.4	.	37.9	58.6	3.4	.	42.9	57.1	.
Case 10: Model= M_2 , JP=(10,23), APC=(0%, -5%, 0%)												
(0.7,10)	.	81.7	18.2	0.1	2.0	96.3	1.7	.	36.2	63.1	0.7	.
(0,60)	.	90.6	9.2	0.2	5.4	93.0	1.6	.	43.7	55.8	0.5	.
(0.4,5)	.	11.8	87.6	0.6	.	89.1	10.9	.	0.5	94.5	5.0	.
(0,20)	.	50.4	49.2	0.4	.	95.5	4.4	0.1	1.8	96.2	1.9	0.1
(0.1,2)	.	.	99.1	0.9	.	29.3	70.0	0.7	.	64.3	35.5	0.2
(0,4)	.	0.2	99.6	0.2	.	62.1	37.9	.	.	75.0	25.0	.
Case 11: Model= M_2 , JP=(10,23), APC=(0%, -5%, -2%)												
(0.7,10)	.	95.0	4.9	0.1	2.6	96.4	1.0	.	34.6	64.7	0.7	.
(0,60)	.	98.0	1.9	0.1	3.9	95.5	0.6	.	37.9	61.8	0.3	.
(0.4,5)	.	72.6	27.4	.	.	97.9	2.1	.	0.2	98.4	1.4	.
(0,20)	.	88.8	11.2	.	.	98.2	1.7	0.1	1.0	98.4	0.6	.
(0.1,2)	.	7.9	91.7	0.4	.	80.6	19.3	0.1	.	90.6	9.4	.
(0,4)	.	28.3	71.4	0.4	.	88.3	11.7	.	.	92.3	7.7	.
Case 12: Model= M_2 , JP=(15,23), APC=(0%, -5%, 0%)												
(0.7,10)	.	80.4	19.6	.	10.2	87.9	1.9	.	49.1	50.3	0.6	.
(0,60)	.	89.5	10.5	.	18.1	80.9	1.0	.	63.3	36.4	0.3	.
(0.4,5)	.	12.7	87.1	0.2	.	88.3	11.6	0.1	0.6	95.0	4.4	.
(0,20)	.	55.8	44.2	.	.	95.9	4.1	.	6.9	91.5	1.6	.
(0.1,2)	.	.	99.3	0.7	.	41.5	58.0	0.5	.	71.5	28.4	0.1
(0,4)	.	.	99.6	0.4	.	68.9	31.1	.	.	100.0	.	.
Case 13: Model= M_2 , JP=(15,23), APC=(0%, -5%, -2%)												
(0.7,10)	.	96.0	3.9	0.1	5.0	94.2	0.8	.	41.5	58.1	0.4	.
(0,60)	.	96.7	3.2	0.1	13.5	85.9	0.6	.	61.2	38.4	0.4	.
(0.4,5)	.	77.0	23.0	.	.	97.7	2.3	.	0.2	98.5	1.2	0.1
(0,20)	.	90.9	9.1	.	.	99.0	0.9	0.1	3.6	95.6	0.8	.
(0.1,2)	.	12.9	86.3	0.8	.	82.0	17.8	0.2	.	90.7	9.2	0.1
(0,4)	.	34.0	66.0	.	.	88.1	11.9	.	.	100.0	.	.

Table 3: Estimates of the joinpoints and the APC of annual death (hazard) rates for selected cancer sites


Cancer site	Case # per year	K	Joinpoints	APC
Male/All Sites	43173	3	(88, 92, 95)	(-2.1*, -8.5*, 0.7, -2.4)
Female/All Sites	40396	2	(82, 86)	(0.5, -2.9*, -1.4*)
Male/Non-prostate	31470	1	93	(-1.3*, -1.9*)
Female/Non-breast	28039	2	(81, 94)	(0.9*, -0.6*, -1.5*)
Distant Testicular	69	2	(77, 93)	(-32.2*, -4.2, 4.2)
Distant Pancreatic	1043	1	95	(-0.3*, -2.9*)
Regional Melanoma	261	1	98	(-1.1*, -14.8*)

Figure 2: The trends of 1-, 3- and 5-year relative survival rates by the year of diagnosis


a. Male/All sites



b. Female/All sites



c. Male/Non-prostate



c. Female/Non-breast






Figure 3: The trends of 1-, 3- and 5-year relative survival rates by the year of diagnosis

a. Distant testicular



b. Distant pancreatic



c. Regional melanoma

